Filing Details

Accession Number:
0001209191-19-049105
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-10 21:05:35
Reporting Period:
2019-09-09
Accepted Time:
2019-09-10 21:05:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1080709 Arena Pharmaceuticals Inc ARNA Pharmaceutical Preparations (2834) 232908305
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1657494 Vincent Aurentz C/O Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego CA 92121
Executive Vp And Cbo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-09-09 25,000 $17.10 25,000 No 4 M Direct
Common Stock Acquisiton 2019-09-09 10,000 $14.60 35,000 No 4 M Direct
Common Stock Acquisiton 2019-09-09 30,000 $35.60 65,000 No 4 M Direct
Common Stock Disposition 2019-09-09 44,672 $50.48 20,328 No 4 S Direct
Common Stock Disposition 2019-09-09 20,328 $51.23 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2019-09-09 25,000 $0.00 25,000 $17.10
Common Stock Employee Stock Option (right to buy) Disposition 2019-09-09 10,000 $0.00 10,000 $14.60
Common Stock Employee Stock Option (right to buy) Disposition 2019-09-09 30,000 $0.00 30,000 $35.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
55,000 2023-08-15 No 4 M Direct
89,500 2024-02-13 No 4 M Direct
100,000 2025-01-19 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.05 to $50.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes 2 and 3 to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.54, inclusive.
  4. The options vest over four years and are exercisable once vested. 25% vested and became exercisable on August 15, 2017. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on September 15, 2017, and the thirty-sixth installment vesting on August 15, 2020.
  5. The options vest over four years and are exercisable once vested. 25% vested and became exercisable on February 13, 2018. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on March 13, 2018, and the thirty-sixth installment vesting on February 13, 2021.
  6. The options vest over four years and are exercisable once vested. 25% vested and became exercisable on January 19, 2019. The remainder of the options vest in thirty-six equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share), with the first installment vesting on February 19, 2019, and the thirty-sixth installment vesting on January 19, 2022.